Máj- és epeúti rák: vizsgálatok itt: Kína
621 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- No phaseCsak meghívásosObservational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
- Where
- Beijing, Guangzhou, Jinan, Shanghai, Xi'an, Xi’an
- Életkor
- 18 év and over
- People
- 100
- Run by
- GrandPharma (China) Co., Ltd.
See details and how to joinNCT06712017 - No phaseTaking peopleThe Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 116
- Run by
- Sun Yat-sen University
See details and how to joinNCT06609850 - No phaseTaking peopledTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 27
- Run by
- Sun Yat-sen University
See details and how to joinNCT06609863 - No phaseTaking peopleDonafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 108
- Run by
- Sun Yat-sen University
See details and how to joinNCT06609876 - 2. fázisTaking peopleDownstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 59
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT05475613 - No phaseTaking peopleEfficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
- Where
- Guangzhou
- Életkor
- 18 év to 65 év
- People
- 60
- Run by
- Third Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT05484908 - No phaseNot yet taking people in KínaCombination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
- Where
- Guiping
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Guiping People's Hospital
See details and how to joinNCT06708650 - 2. fázisTaking peoplePhase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 35
- Run by
- Dai, Guanghai
See details and how to joinNCT06708858 - Korai 1. fázisTaking peopleClinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 12
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT06652243 - 2. fázisTaking peopleRituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
- Where
- Tianjin
- Életkor
- 17 év to 79 év
- People
- 20
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06301399 - No phaseTaking peopleIntravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
- Where
- Nanjing
- Életkor
- 25 év to 75 év
- People
- 5
- Run by
- Zhongda Hospital
See details and how to joinNCT06694636 - 2. fázisTaking peopleCombination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 140
- Run by
- Sun Yat-sen University
See details and how to joinNCT06313190 - 1. fázisTaking peopleClinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
- Where
- Hangzhou
- Életkor
- 18 év to 70 év
- People
- 15
- Run by
- Zhejiang University
See details and how to joinNCT06461624 - 2/3. fázisNot yet taking people in KínaAnlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 206
- Run by
- Sun Yat-sen University
See details and how to joinNCT06662877 - No phaseTaking peopleA Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
- Where
- Hefei
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
See details and how to joinNCT06611345 - No phaseNot yet taking people in KínaA Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06658587 - 4. fázisTaking peopleDEB-TACE Prior to Liver Transplantation in the Treatment of HCC
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- RenJi Hospital
See details and how to joinNCT06353126 - 2. fázisNot yet taking people in KínaAdebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
- Where
- Harbin
- Életkor
- 18 év to 75 év
- People
- 68
- Run by
- Harbin Medical University
See details and how to joinNCT06648525 - 2. fázisTaking peopleTIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Fei Gao
See details and how to joinNCT06646198 - No phaseCsak meghívásosA Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
- Where
- Guangzhou
- Életkor
- 18 év to 80 év
- People
- 1500
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT06647264 - 1/2. fázisNot yet taking people in KínaCAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT06641453 - No phaseTaking peopleNeoadjuvant Triple Therapy for Resectable HCC
- Where
- Fuzhou, Xiamen, Zhangzhou
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Fujian Provincial Hospital
See details and how to joinNCT06569498 - No phaseTaking peopleTriple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
- Where
- Fuzhou, Xiamen, Zhangzhou
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Fujian Provincial Hospital
See details and how to joinNCT06602011 - No phaseTaking peopleCorrelation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
- Where
- Guangzhou
- Életkor
- 18 év to 80 év
- People
- 900
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT06623474 - 2. fázisNot yet taking people in KínaClinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 46
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT06632522